Clinical Trial Update: Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine. [Phase 3]

View source ↗

Summary

Phase 3 results evaluating a GSK Tdap booster vaccine candidate for immunogenicity and safety in children and adolescents previously given five acellular pertus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Tdap booster vaccine candidate

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Diphtheria | Phase 3 | Status: COMPLETED